| 초록 |
Immunotherapy has attracted attention as a promising next generation anticancer therapy. However, therapeutic efficiency of immunotherapy agents such as immune checkpoint inhibitor and CAR-T cell is limited due to the tumor microenvironment (TME) conditions. Herein, to overcome this drawback, polycationic polymer-based biocompatibility-controllable immuno-sensitizer (PCI) was developed. PCI triggers in situ tumor destruction through the biocompatibility conversion in response to TME. As a result, in situ tumor destruction and the consequential tumor antigen release induce dendritic cells (DCs) maturation and cytotoxic T lymphocytes (CTLs) response leading powerful antitumor immune response. Antitumor immune response was confirmed by the tumor re-challenge experiments. Therefore, these results may reveal the potential of polymer-based immunotherapeutic agent platform for the advanced immunotherapy. |
